To further explore the clinical value of these biomarkers, we evaluated whether 6 of our differentially methylated genes—ADCY4, CPXM1, DNM3, PRDM14, PRKCB, and ZNF177—had any relation with overall survival of breast cancer patients. The gene discussed is ADCY4; the disease is breast cancer.